Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII)

Laryngoscope

Volumn 116, Issue 5, 2006, Pages 814-820

  Khariwala, Samir S ^a   Kjaergaard, Jorgen ^a   Lorenz, Robert ^a   Van Lente, Frederick ^a   Shu, Suyu ^a   Strome, Marshall ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Everolimus; Immunosuppression; Squamous cell carcinoma

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAD; DRUG DERIVATIVE; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; GRAFT RECIPIENT; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; ANIMAL; C3H MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; COMPARATIVE STUDY; DISEASE MODEL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; METASTASIS; PATHOLOGY; PROBABILITY; RANDOMIZATION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; PROBABILITY; RANDOM ALLOCATION; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SIROLIMUS; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 33745245286     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlg.0000210544.64659.35     Document Type: Article

References (31)

1. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998:147-158.
2. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 2002;3:295-304.
3. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 1995;60: 264-270.
4. s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 1996;56: 3895-3897.
5. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-1323.
6. Sedrani R, Cottens S, Kallen J, Schuler WL. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc 1998;30:2192-2194.
7. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64:36-42.
8. Kahan BD, Kaplan B, Lorber MI, Winkler M, Cambon N, Boger RS. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001;71:1400-1406.
9. Schuurman HJ, Schuler W, Ringers J, Jonker M. The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc 1998;30: 2198-2199.
10. Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 2002;73:920-925.
11. Kovarik JM, Eisen H, Dorent R, et al. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. J Heart Lung Transplant 2003;22:1117-1125.
12. Farb A, John M, Acampado E, Kolodgie FD, Prescott MF, Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation 2002;106:2379-2384.
13. Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A 2000;97:4285.
14. Boulay A, Zumstein-Mecker S, Stephan C. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004;64:252-261.
15. Knott PD, Tamai H, Shimizu K, et al. Everolimus (RAD) inhibition of MCA205 sarcoma growth: a murine model. In press.
16. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996;14:483.
17. Schmidbauer G, Hancock W, Wasowska B, et al. Abrogation by rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and endothelial cell activation, cytokine production and cell adhesion. Transplantation 1998;66:1387.
18. Neuhas P, Klupp J, Langrehr JM. mTor inhibitors: an overview. Liver Transpl 2001;7:473.
19. Hoyer PF, Ettenger R, Kovarik JM, et al. Everolimus in pediatric de novo renal transplant patients. Transplantation 2003;75:2082-2085.
20. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349: 847-858.
21. Knott PD, Nelson M, Dan O, Van Lente F, Strome M. Immunosuppressive efficacy of everolimus and tacrolimus combination therapy in a rat laryngeal transplant model. In press.
22. Khariwala SS, Knott PD, Dan O, et al. Pulsed immunosuppression with everolimus and anti-αβTCR: laryngeal allograft preservation at 6 months. Ann Otol Rhinol Laryngol 2006;115:74-80.
23. Beuvink I, O'Reilly T, Zumstein-Mecker S, et al. Antitumor activity of RAD001, an orally active rapamycin derivative. Proc Am Assoc Cancer Res 2001;42:366.
24. O'Reilly T, Vaxclaire J, Muller M, et al. In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Assoc Cancer Res 2002;43: 71.
25. McGeown MG, Douglas JF, Middleton D. One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporinbased regimes in a single centre. Clin Transpl 2000: 193-202.
26. Jonas S, Rayes N, Neumann U, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997;80:1141-1150.
27. Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73:1565-1572.
28. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993;5:806.
29. Hashemolhosseini S, Nagamine Y, Morley SJ, et al. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998;273:14424.
30. rd ed. 1998;3:2130-2175.
31. th ed. 1999:549-572.